ADA’s Scientific Sessions: Day 1
Here are Drs. Candace Reno and Luiza Caramori share their key takeaways from day 1, with their commentary in the…
Artificial Intelligence Identifies T1D Risk Factors in Children
Breakthrough T1D and IBM Research have published their first paper, applying world-class computing power to identify factors leading to the…
Breakthrough T1D Heads, Virtually, to ADA’s 81st Scientific Sessions
At the ADA's 81st Scientific Sessions, healthcare professionals will gather at one of the largest conferences of diabetes researchers in…
T1D Doesn’t Discriminate: Know Your Risk with T1Detect
How Breakthrough T1D’s screening education and awareness program can help address health disparities experienced by underserved members of the T1D…
Just in Time for Father’s Day: Husband, Dad of T1D Family Shares His Experiences
Peterson Cilaire, husband and father of a T1D family, on loving someone who lives with T1D, learning to manage T1D…
FDA Advisory Committee Recommends that Teplizumab Receives Approval
An FDA Advisory Committee weighed the evidence, and the results were positive: They recommended that the FDA approve teplizumab for…
Advancing Cures with Type 1 Diabetes Clinical Trials
May 20 is Clinical Trials Day, a day to raise awareness of clinical research and the people around the world…
50+ Years with Type 1: An Interview with Dr. George King
I got the privilege of interviewing George King, M.D., whose research is on diabetes complications. Breakthrough T1D has funded him…
Bigfoot Is Real—and Received FDA Clearance
The Bigfoot Unity™ Diabetes Management by Bigfoot Biomedical received FDA clearance for individuals 12 and older.
At 37, I’m Fighting to Save my Eyesight
At the age of 37, I’m fighting to save my eyesight, a complication of type 1. People are also at…
